1 / 35

Office of In Vitro Diagnostic Device Evaluation and Safety

Office of In Vitro Diagnostic Device Evaluation and Safety. Donald St.Pierre Deputy Director for New Device Evaluation AdvaMed’s 13 th Annual Device Submissions Workshop. The Story Line. Organization & Resources Workload Review Statistics MDUFMA. ORGANIZATION & RESOURCES.

lilly
Download Presentation

Office of In Vitro Diagnostic Device Evaluation and Safety

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Office of In Vitro Diagnostic Device Evaluation and Safety Donald St.Pierre Deputy Director for New Device Evaluation AdvaMed’s 13th Annual Device Submissions Workshop

  2. The Story Line • Organization & Resources • Workload • Review Statistics • MDUFMA

  3. ORGANIZATION &RESOURCES

  4. Structure - OIVD • Single Organizational Unit • Premarket • Compliance • Post-market • One Stop Shopping • Delayered – no more branches • Streamlined – minimal administrative support

  5. OIVD (con’t) • Goals • Increased Transparency • Uniform Least Burdensome Approach • Expedited Technology Transfer • Improve Connectivity and Quality of Work • Objective - TPLC • Common Technical Base • Faster Response Time

  6. SEE ORGANIZATIONAL CHART

  7. Thanks to MDUFMA • Approaching FY01 Staffing Level • 11th Annual Workshop – 66 • 12th Annual Workshop – 54 • 13th Annual Workshop – 63 • Doug Wood (DCTD - 5/18) • Cecily Jones (DIHD – 6/1) • Marieanne Brill (DMD – 6/1) • 3 more are in-process • Total Projected --70-75 by EOY

  8. Parallel to other offices • ODE • Same commitments, responsibilities • Adopt spirit of LB, summaries/balance • OC • Same commitments, responsibilities • Still learning, moving 510(k)s this direction, 30-day notice changes, tracking, MOU • OSB • Eggs in MedSun basket • Move from MDRs to active surveillance

  9. Other Offices - Projects • OST • Software support • Guidance collaboration • OHIP • Still some pt labeling/human factors • OIVD website • OSM • Collaborative software, databases, tracking, eReview

  10. External Outreach • IVD Roundtable • Professional IVD Roundtable • Pharmacogenomic Roundtable • Therapeutic Drug Management RT • Internal Staff College • NIH/NCI • CDC/CMS • SAMHSA

  11. II. WORKLOAD

  12. PMA Receipts (½ FY03)

  13. 510(k) Receipts (½ FY03)

  14. Other OIVD Documents

  15. Other Receipts (½ FY03)

  16. Standards Activities • 5 revised • 4 withdrawn • 15 new (See 4/28/03 FR notice)

  17. GHTF • CDRH active in all Study Groups (SG); OIVD active in SG 1 (POC - Ginette Michaud) • SG1: operational aspects of medical device regulation including IVD products Current IVD harmonization projects: • classification • labeling • IVD premarket conformity with principles for safety and performance • STED (?)

  18. FY03 Guidance Documents • Multiplex Tests for Heritable DNA Markers, Mutations and Expression Patterns • Antimicrobial Susceptibility Test (AST) Systems • Analyte Specific Reagents; Small Entity Compliance Guidance

  19. Guidances In-the-Works • Coagulation • NIOX and 1 other Denovo • Replacement Reagent • Glucose • IVD Device Studies (BiMo)

  20. OIVD Counter Terrorism Activities • Established emergency response plans, in conjunction with HHS and FDA, to monitor and respond to a terrorist event  • Expediting the review of device submissions related to counter terrorism and military need • Evaluating the safety and effectiveness of diagnostic test kits that detect biothreat agents • Participated in TOPOFF Exercise

  21. Other Resource Issues • Classifications – Herpes, B. Anthracis, Yersinia Pestis • Scorecards • CBER/CDRH interactions • CPI • TPLC/Patient Safety • SARS/WNV • ASRs/Genetics • CLIA/OC

  22. On the Web FY03 • 510(k) - IDI Strep B for Preg. Women • 510(k) - pro-BNP for CHF • 510(k) - Home Glycated Hemoglobin for Diabetics • 510(k) - Cobalt Albumin to rule out Heart Attack • 510(k) - Breath test for Asthma • 510(k) - Aspergillus

  23. On the Web FY03 • Lab Safety Tips • Accu Chek class II Recall • SSED - P020027 (FPSA) • SSED - P020011 (HCV) • IVD 510(k) Workshop • Expanded use for HPV • Consumer Information

  24. Ongoing Activities • Performance Scorecards • Looking for measurable outcomes (e.g.,) • Decrease enforcement actions • Decrease recalls • Decrease MDRs • Decrease review times • Increase decision quality • Improve BiMo audit results • Measure feedback

  25. Ongoing Activities • New IVD Webpage (good first effort) • www.fda.gov/cdrh/oivd • Standardizing review format • Learning about compliance • Learning about post-market • MedSun to LabSun • Post-market safety team

  26. Post-Market Safety Team - Themes • Consumer education/outreach • Internal training (522 authority, STAMP, safety alerts, public health advisories/notifications, MDRs, MedWatch, MedSun) • Tap Epi group – databases/literature • Pick a disease and focus • Active Surveillance ideas

  27. Review Statistics

  28. Original PMA Approvals

  29. PMA Supplement Approvals

  30. ½ FY03 510(k) Review Stats

  31. 510(k) Review Stats

  32. CLIA Workload

  33. IV. MDUFMA Participating on implementation teams Providing input on Guidances Clarifying terminology Bundling

  34. Bundling Principles • Historically Done – continue • Not Historically Done – don’t, unless it makes sense & can be reviewed efficiently • Second thoughts on our part (e.g., HBV) • Guidance Coming • No fee for Replacement Reagents

  35. Challenges for the New Millennium • CLIA waiver • Genetic Diseases/ASRs • Microarrays/High throughput assays • Turbo 510(k) • TPLC • Integrating all the work of the Center into OIVD

More Related